couter

600211.SSTibet Rhodiola Pharmaceutical Holding Co. Class A

Health CarePharmaceuticals
Oct 28, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Wed28Oct

    Tibet Rhodiola reports Q3 2026 results with the market focused on whether the recent -11.48% YoY revenue contraction is stabilizing or accelerating.

  • Tue15Dec

    China's National Healthcare Security Administration (NHSA) announces the updated National Reimbursement Drug List (NRDL), directly impacting pricing power for Tibet Rhodiola's core TCM and cardiovascular portfolio.

  • Tue20Apr
  • Tue15Jun